6th Gynaecological Cancer Academy Workshop

The 6th Gynaecological Cancer Academy Workshop with joint sessions of ENGOT Translational Research Network and Phase 1-2 Network, was held in London in September 2015.

The opening session of the workshop challenged the topic 'How to classify patients with recurrent ovarian cancer'. For several decades, the recurrent ovarian cancer has been classified according to platinum-free interval. However, in the era of new target therapies, this classification may not be relevant and a molecular classification might be more appropriate.

In addition, the session ´Challenges in defining the criteria for response and progression in clinical trials´ challenged a critical discussion about usage of Response Evaluation Criteria In Solid Tumors (RECIST) criteria, Immune related Response Criteria (irRC), CA-125 and their variations in trials, and questioned their usage in the era of the era of targeted and immunologic therapies.

Interested to find out more?

Watch the free access* webcasts below from the 6th GCA Workshop.

*First time eAcademy users need to register for a free access account.

>>Start the process

 

 

Nicoletta Colombo, Italy

Welcome and introduction: The changing landscape of clinical trials in the era of targeted and immunologic therapies: different patient selection, new endpoints, new responsible criteria

   

 

SESSION 1: HOW TO CLASSIFY PATIENTS WITH RECURRENT OVARIAN CANCER?

Mansoor Raza Mirza, Denmark

Debate: platinum-free interval is still a valid tool in guiding treatment decision - PRO

   

Jonathan A Ledermann, UK

How to define platinum-resistance or sensitivity after several lines of treatment?

   

Sandro Pignata, Italy

Debate: platinum-free interval is still a valid tool in guiding treatment decision - CON

   

Bradley Monk, USA

How to measure the benefit of chemotherapy-free interval in a trial with maintenance targeted therapy? The importance combined endpoints

   
SESSION 2: JOINT MEETING TR GROUP, PHASE 1-2 GROUP AND GCA ATTENDEES

 

Iain McNeish, UK

Potential actionable target pathways in the different types of ovarian cancer

 

Cristiana Sessa, Switzerland

Available drugs targeting the known altered pathways in ovarian cancer

9th GCA workshop

November 17-18, 2017, Milan, Italy

Sheraton Milan Malpensa Airport Hotel

Don't miss out, Save the Date!

You May Also Like

GCA WORKSHOPS

Watch the Webcasts 

 

Read More

CLINICAL TRIALS

Latest Published Research

 

Read More

FOR PATIENTS

Key Insights

 

Read More

ESGO 2017 Congress

Clinical Trials Session

 

Read More